Tamoxifen maculopathy: The importance of screening and long follow-up
| Autor: | Davide Borroni, M. Rodríguez Calvo de Mora, M. España Contreras, C. Rocha-de-Lossada, R. Rachwani Anil, F. Zamorano Martín |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty genetic structures medicine.medical_treatment Breast Neoplasms Asymptomatic Macular Degeneration Breast cancer Retinal Diseases Antineoplastic Combined Chemotherapy Protocols medicine Humans Macula Lutea Fluorescein Angiography skin and connective tissue diseases Pathological Aged Monitoring Physiologic business.industry Toxic maculopathy medicine.disease eye diseases Discontinuation Ophthalmology Tamoxifen Maculopathy Female sense organs Hormone therapy medicine.symptom business Tomography Optical Coherence medicine.drug Follow-Up Studies |
| Zdroj: | Journal francais d'ophtalmologie. 43(8) |
| ISSN: | 1773-0597 |
| Popis: | We report a case of a patient treated with tamoxifen 20mg daily as hormone therapy for breast cancer. On regular ophthalmological follow-up, tamoxifen maculopathy was detected on SD-OCT (Spectral Domain Optic Coherence Tomography, Carl Zeiss Meditec®), so the medication was discontinued. Despite discontinuation of the medication, the maculopathy progressed over time. We have been following our patient for seven years. Tamoxifen may produce a toxic maculopathy which may progress despite discontinuation of the medication. We consider our case interesting, given the lengthy follow-up of the patient with sequential SD-OCT images. To the best of our knowledge, our case represents the longest follow-up period for a patient with tamoxifen maculopathy. Moreover, we would like to stress the importance of screening in asymptomatic patients on this medication, in order to detect early pathological signs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|